Back to top
more

Assembly Biosciences (ASMB)

(Real Time Quote from BATS)

$13.58 USD

13.58
3,745

+0.10 (0.74%)

Updated Apr 25, 2024 11:08 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (159 out of 251)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Company Summary

Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York.

General Information

Assembly Biosciences, Inc

TWO TOWER PLACE 7TH FLOOR

SOUTH SAN FRANCISCO, CA 94080

Phone: 833-509-4583

Fax: 646-706-5101

Web: http://www.assemblybio.com

Email: sryan@assemblybio.com

Industry Medical - Generic Drugs
Sector Medical
Fiscal Year End December
Last Reported Quarter 3/31/2024
Exp Earnings Date

This is an estimated date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.

 5/2/2024

EPS Information

Current Quarter EPS Consensus Estimate -2.74
Current Year EPS Consensus Estimate -12.65
Estimated Long-Term EPS Growth Rate NA
Exp Earnings Date

This is an estimated date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.

 5/2/2024

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 13.48
52 Week High 20.04
52 Week Low 7.69
Beta 0.57
20 Day Moving Average 18,390.85
Target Price Consensus 36.00

ASMB

% Price Change
4 Week 0.75
12 Week 19.44
YTD 36.92
% Price Change Relative to S&P 500
4 Week 4.26
12 Week 14.12
YTD 28.77
Share Information
Shares Outstanding (millions) 5.48
Market Capitalization (millions) 73.91
Short Ratio NA
Last Split Date 7/14/2014
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio NA
Change in Payout Ratio NA
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E
P/E (F1) NA
Trailing 12 Months NA
PEG Ratio NA
EPS Growth
vs. Previous Year 43.75%
vs. Previous Quarter 15.62%
   
Sales Growth
vs. Previous Year NA%
vs. Previous Quarter NA%
   
Price Ratios
Price/Book 1.80
Price/Cash Flow NA
Price / Sales NA
ROE
3/31/24 NA
12/31/23 -117.69
9/30/23 -116.42
ROA
3/31/24 NA
12/31/23 -72.43
9/30/23 -95.89
Current Ratio
3/31/24 NA
12/31/23 3.41
9/30/23 6.96
Quick Ratio
3/31/24 NA
12/31/23 3.41
9/30/23 6.96
Operating Margin
3/31/24 NA
12/31/23 NA
9/30/23 NA
Net Margin
3/31/24 NA
12/31/23 NA
9/30/23 NA
Pre-Tax Margin
3/31/24 NA
12/31/23 -854.32
9/30/23 NA
Book Value
3/31/24 NA
12/31/23 7.50
9/30/23 9.52
Inventory Turnover
3/31/24 NA
12/31/23 NA
9/30/23 NA
Debt-to-Equity
3/31/24 NA
12/31/23 0.00
9/30/23 0.00
Debt to Capital
3/31/24 NA
12/31/23 0.00
9/30/23 0.00